Exact Sciences (EXAS) Is Up 11.2% After Launching Cancerguard Multi-Cancer Blood Test With Quest Diagnostics

• Exact Sciences Corp. recently announced the launch of Cancerguard™, a new multi-cancer early detection blood test now available as a laboratory-developed test in the U.S., which detects over 50 cancer types and is supported by data from more than 20,000 participants.
• This marks the first commercially available MCED test analyzing multiple biomarker classes, supported by a national patient access partnership with Quest Diagnostics, to address significant unmet cancer screening needs.
• We'll explore how the national rollout of Cancerguard via Quest Diagnostics could reshape Exact Sciences' future growth outlook.

We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Exact Sciences Investment Narrative Recap

To be a shareholder in Exact Sciences, you have to believe in the transformative power of early cancer detection and the company’s ability to commercialize innovative screening solutions at scale. The Cancerguard™ launch directly targets unmet screening needs and could accelerate Exact’s transition beyond reliance on Cologuard, creating a visible short-term catalyst, but uptake will likely hinge on payer coverage and guideline endorsement, areas that remain the company’s riskiest hurdles.

One of the most relevant recent announcements is the partnership with Quest Diagnostics, which enables Cancerguard’s nationwide access and integrates blood collection across approximately 7,000 sites. This expanded distribution could drive near-term test adoption, supporting Exact’s ambitions in multi-cancer early detection while amplifying the importance of broad clinical and payer acceptance.

On the other hand, investors should be aware of how uncertainty around insurance reimbursement might limit Cancerguard’s near-term growth opportunity and ...

Read the full narrative on Exact Sciences (it's free!)

Exact Sciences’ narrative projects $4.1 billion revenue and $277.2 million earnings by 2028. This requires 11.6% yearly revenue growth and a $1.28 billion increase in earnings from -$1.0 billion today.

Uncover how Exact Sciences' forecasts yield a $63.14 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community range from US$63.14 to US$103.77 per share. With opinions reflecting wide variance, keep in mind that real-world clinical and payer adoption may become decisive for Exact Sciences’ performance.

Explore 6 other fair value estimates on Exact Sciences - why the stock might be worth just $63.14!

Build Your Own Exact Sciences Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Exact Sciences research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Exact Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exact Sciences' overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com